BioLife Solutions, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $3.00K, a 83.33% decline year-over-year.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $189.00K.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $18.00K, a 91.09% decline from fiscal 2024.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $202.00K, a 60.16% decline from fiscal 2023.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $507.00K, a 56.97% increase from fiscal 2022.
- BioLife Solutions, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $323.00K, a 77.22% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $3.00K 10-Q · filed 2026-08-06 | $192.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $189.00K 10-Q · filed 2026-05-07 | $207.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | $18.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $202.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $46.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $91.00K 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $507.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $64.00K 10-Q · filed 2024-11-12 | $386.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $181.00K 10-Q · filed 2024-08-09 | $328.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $125.00K 10-Q · filed 2024-05-10 | $190.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $323.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $6.00K 10-Q · filed 2023-11-09 | $707.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $43.00K 10-Q · filed 2023-08-09 | $1.11M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $257.00K 10-Q · filed 2023-05-11 | $1.43M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.42M 10-K · filed 2024-02-29 |
| 2021-09-30 | $408.00K 10-Q · filed 2022-11-09 | $1.46M derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-06-30 | $364.00K 10-Q · filed 2022-08-09 | $1.29M derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-03-31 | $243.00K 10-Q · filed 2022-05-10 | $1.22M derived: sum of 4 quarters · filed 2023-03-31 |
| 2020-12-31 | $444.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.47M 10-K · filed 2023-03-31 |
| 2020-09-30 | $244.00K 10-Q · filed 2021-11-15 | $1.37M derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-06-30 | $293.00K 10-Q · filed 2021-08-16 | $1.50M derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-03-31 | $490.00K 10-Q · filed 2021-05-17 | $1.51M derived: sum of 4 quarters · filed 2022-03-31 |
| 2019-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.18M 10-K · filed 2022-03-31 |
| 2019-09-30 | $378.00K 10-Q · filed 2020-11-09 | -$10.38M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $301.00K 10-Q · filed 2020-08-10 | -$7.93M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $161.00K 10-Q · filed 2020-05-29 | $597.00K derived: sum of 4 quarters · filed 2020-05-29 |
| 2018-12-31 | -$11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-15 | $508.00K 10-K · filed 2020-05-15 |
| 2018-09-30 | $2.83M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $8.83M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $73.00K 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $3.98M 10-K · filed 2019-03-15 | |
| 2016-12-31 | $246.28K 10-K · filed 2018-03-09 | |
| 2015-12-31 | $400.98K 10-K · filed 2017-03-15 | |
| 2014-12-31 | $83.59K 10-K · filed 2016-02-25 | |
| 2013-12-31 | $50.46K 10-K · filed 2014-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |